Clinical trials
Gastric / Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting gastric / gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 176 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05403242RecruitingPhase 1/Phase 2
Study drug RC48-ADC plus S-1 for advanced HER2 stomach cancers
This Phase 1/2 study tests RC48-ADC (an antibody-drug treatment) together with S-1 (a chemotherapy medicine) in people with advanced stomach or esophagus/gastroesophageal junction cancer. It’s mainly for cancers with HER2 testing results of IHC 2+ and FISH-negative, and aims to find a safe dose and how well the treatment works as a first treatment option.
BeijingAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Newport Beach, CaliforniaAges 18 years+ - NCT06929949Recruiting
Best Reconnection Method After Upper Stomach Surgery
This study compares different ways of reconnecting the digestive tract after surgery to remove the upper part of the stomach. It aims to see which method leads to a better quality of life for people with early-stage stomach or esophageal junction cancer.
Changchun, JilinAges 18–75 - NCT07110571RecruitingPhase 2
Combination therapy study for untreated stomach or GEJ cancer
This trial tests a combination of adebrelimab (an immunotherapy) with either two other experimental drugs (SHR-A1811 or SHR-A1904) plus chemotherapy, or another drug (SHR-8068), as a first treatment for gastric or gastroesophageal junction adenocarcinoma. It aims to find if these combos work better than standard care.
Shijiazhuang, HebeiAges 18–70 - NCT06300879Recruiting
New surgery technique for upper stomach or junction cancer
This study tests a new surgical technique for removing cancer in the upper stomach or where the stomach meets the esophagus. It aims to see if this technique is safe and effective for people with early-stage adenocarcinoma who haven't had other cancer treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07533825Enrolling by invitation
Minimally Invasive Surgery Staging for Advanced Stomach Cancer
This trial tests whether a minimally invasive camera-guided surgical procedure (laparoscopy) can better detect hidden cancer spread in patients with advanced stomach cancer. The goal is to help doctors plan the best treatment and improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07464756RecruitingPhase 2
Study of SHR-1701 and apatinib with chemo before stomach cancer surgery
This trial tests whether adding SHR-1701 (an immunotherapy) with or without apatinib (a targeted therapy) to standard chemotherapy before surgery can help treat gastric cancer. It is for people with stomach or gastroesophageal junction cancer that has spread to nearby lymph nodes but is still removable.
Nanjing, JiangsuAges 18 years+ - NCT07178808RecruitingPhase 2
Surgery and heated chemotherapy for stomach cancer
This trial tests if surgery to remove visible cancer in the belly combined with heated chemotherapy placed directly into the abdomen can help people with stomach cancer that has spread to the lining of the belly. It is for patients who are well enough to undergo major surgery and meet specific health requirements.
Gilbert, ArizonaAges 18 years+ - NCT06798376Recruiting
Immunotherapy plus chemo before stomach cancer surgery
This trial tests combining immunotherapy (PD-1 blockers) with chemotherapy before surgery for advanced stomach cancer. The goal is to find the best number of treatment cycles to shrink the tumor and improve surgery results.
BeijingAges 18–90 - NCT07034742RecruitingEarly Phase 1
MRD testing after stomach cancer surgery
This study looks at whether a blood test for leftover cancer cells (called MRD) after stomach cancer surgery can help guide treatment. It is for people with a certain type of stomach cancer that has spread to nearby tissues but not to distant organs, and who are having surgery as their first treatment.
BeijingAges 18–75 - NCT05177133RecruitingPhase 2
First-line treatment for MSI-high stomach or esophagus cancer
This Phase 2 trial tests whether adding an anti–PD-1 immunotherapy (retifanlimab) and chemotherapy (capecitabine plus oxaliplatin, with leucovorin) works better for people with metastatic or inoperable stomach or gastroesophageal junction cancer that has defective mismatch repair (dMMR). If you’re eligible, it may help shrink tumors and slow the disease without needing prior chemotherapy for metastatic cancer.
AmsterdamAges 18 years+ - NCT06702683Recruiting
Sintilimab blood levels in advanced stomach cancer
This study looks at how the amount of Sintilimab in your blood relates to how well it works and what side effects you might have. If you have advanced stomach cancer and are planning to get Sintilimab, this trial could help your doctor find the best dose for you.
Nanjing, JiangsuAges 18 years+ - NCT07149090RecruitingPhase 1/Phase 2
Lenvatinib, Nivolumab, and Chemo in Stomach Cancer with Ascites
This trial tests a combination of two drugs (lenvatinib and nivolumab) plus chemotherapy for people with advanced stomach cancer that has caused fluid buildup in the belly. The goal is to see if this combination can help shrink the cancer and reduce the fluid.
SeoulAges 19 years+ - NCT07392346RecruitingPhase 2
Fruquintinib combo for advanced gastric cancer after immunotherapy
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06468280RecruitingPhase 2
Immunotherapy and chemo with surgery for limited-spread stomach cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
Shanghai, Shanghai CityAges 18–79 - NCT07098026Recruiting
Herbal mixture plus chemo before surgery for advanced stomach cancer
This trial tests whether adding an herbal mixture (Shenqi Fuwei Mixture) to standard chemotherapy before surgery can help treat locally advanced stomach cancer. It is for people whose cancer has not spread to distant sites and who are healthy enough to undergo treatment and surgery.
Changsha, HunanAges 18–75 - NCT05187182RecruitingPhase 1
Testing a new cancer drug with FOLFOX and immune therapy
This Phase 1 study tests CA-4948 given with standard chemotherapy (FOLFOX) and an immune therapy (an immune checkpoint inhibitor, similar to PD-1). It’s for people with advanced stomach or esophageal cancer that can’t be removed by surgery, to see how well the treatment works and whether it’s safe.
St Louis, MissouriAges 18 years+ - NCT03539822RecruitingPhase 1/Phase 2
Cabozantinib and immunotherapy for advanced stomach or bowel cancers
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Westwood, KansasAges 18 years+ - NCT06245356RecruitingPhase 2
A safety trial of trifluridine/tipiracil for DPD-deficient patients
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
AmiensAges 18 years+ - NCT06932068RecruitingPhase 2
Study of new drug combo for advanced stomach cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
Zhengzhou, HenanAges 18–75 - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05813015RecruitingPhase 3
Testing S-1 after stomach cancer surgery with or without sequence therapy
This Phase 3 study compares two ways of giving S-1 medicine after curative stomach cancer surgery in stage III disease. It aims to see whether the sequential approach improves outcomes while keeping treatment safe.
Hanzhou, ZhejiangAges 18–75 - NCT06650332RecruitingPhase 1/Phase 2
Cadonilimab combo for first-line HER2-positive gastric cancer
This trial tests a new combination treatment (cadonilimab plus chemotherapy) as the first therapy for people with advanced gastric or gastroesophageal junction cancer that has a certain amount of HER2 protein. It aims to see if this combination can shrink tumors and help people live longer.
Hangzhou, ZhejiangAges 18–75
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric / gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 176 recruiting gastric / gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric / gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric / gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.